دورية أكاديمية
أعرض في EDS

A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide.

التفاصيل البيبلوغرافية
العنوان: A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide.
المؤلفون: Clavreul A; Université d'Angers, CHU d'Angers, CRCINA, F-49000 Angers, France.; Département de Neurochirurgie, CHU Angers, F-49933 Angers, France., Lemée JM; Université d'Angers, CHU d'Angers, CRCINA, F-49000 Angers, France.; Département de Neurochirurgie, CHU Angers, F-49933 Angers, France., Soulard G; Département de Neurochirurgie, CHU Angers, F-49933 Angers, France., Rousseau A; Université d'Angers, CHU d'Angers, CRCINA, F-49000 Angers, France.; Département de Pathologie Cellulaire et Tissulaire, CHU Angers, F-49933 Angers, France., Menei P; Université d'Angers, CHU d'Angers, CRCINA, F-49000 Angers, France.; Département de Neurochirurgie, CHU Angers, F-49933 Angers, France.
المصدر: Cancers [Cancers (Basel)] 2021 Nov 18; Vol. 13 (22). Date of Electronic Publication: 2021 Nov 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Purpose: The survival times of glioblastoma (GB) patients after the standard therapy including safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide are heterogeneous. In order to define a simple, reliable method for predicting whether patients with isocitrate dehydrogenase (IDH)-wildtype GB treated with the standard therapy will be short- or long-term survivors, we analyzed the correlation of preoperative blood counts and their combined forms with progression-free survival (PFS) and overall survival (OS) in these patients.
Methods: Eighty-five patients with primary IDH-wildtype GB treated with the standard therapy between 2012 and 2019 were analyzed retrospectively. Cox proportional hazards models and Kaplan-Meier analysis were used to investigate the survival function of preoperative hematological parameters.
Results: Preoperative high neutrophil-to-lymphocyte ratio (NLR, >2.42), high platelet count (>236 × 10 9 /L), and low red blood cell (RBC) count (≤4.59 × 10 12 /L) were independent prognostic factors for poorer OS ( p = 0.030, p = 0.030, and p = 0.004, respectively). Moreover, a high NLR was an independent prognostic factor for shorter PFS ( p = 0.010). We also found that, like NLR, preoperative high derived NLR (dNLR, >1.89) was of poor prognostic value for both PFS ( p = 0.002) and OS ( p = 0.033). A significant correlation was observed between NLR and dNLR (r = 0.88, p < 0.001), which had a similar prognostic power for OS (NLR: AUC = 0.58; 95% CI: [0.48; 0.68]; dNLR: AUC = 0.62; 95% CI: [0.51; 0.72]). Two scores, one based on preoperative platelet and RBC counts plus NLR and the other on preoperative platelet and RBC counts plus dNLR, were found to be independent prognostic factors for PFS ( p = 0.006 and p = 0.002, respectively) and OS ( p < 0.001 for both scores).
Conclusion: Cheap, routinely ordered, preoperative assessments of blood markers, such as NLR, dNLR, RBC, and platelet counts, can predict the survival outcomes of patients with IDH-wildtype GB treated with the standard therapy.
References: Cancer Manag Res. 2021 Feb 09;13:1159-1168. (PMID: 33603461)
Clin Neurol Neurosurg. 2020 Oct;197:106162. (PMID: 32890893)
Cancers (Basel). 2021 Feb 01;13(3):. (PMID: 33535436)
PLoS One. 2021 Jun 17;16(6):e0252614. (PMID: 34138894)
Oncology. 2019;97(5):255-263. (PMID: 31288238)
Dis Markers. 2019 Jan 2;2019:7606128. (PMID: 30719182)
Neuro Oncol. 2019 Nov 4;21(11):1458-1469. (PMID: 31346613)
Int J Mol Sci. 2020 Mar 13;21(6):. (PMID: 32182988)
Anticancer Res. 2013 Aug;33(8):3467-74. (PMID: 23898121)
Int J Mol Sci. 2020 May 14;21(10):. (PMID: 32422991)
Genes Dev. 2017 Apr 15;31(8):774-786. (PMID: 28465358)
Exp Ther Med. 2013 May;5(5):1351-1354. (PMID: 23737877)
J Neuropathol Exp Neurol. 2018 Aug 1;77(8):710-716. (PMID: 30010995)
Cancer Biol Med. 2020 Feb 15;17(1):154-168. (PMID: 32296583)
Cancers (Basel). 2019 Apr 22;11(4):. (PMID: 31013620)
Neuro Oncol. 2007 Jul;9(3):335-42. (PMID: 17504931)
Surg Oncol. 2017 Mar;26(1):96-104. (PMID: 28317592)
Sci Rep. 2020 Jul 15;10(1):11622. (PMID: 32669604)
Platelets. 2017 Sep;28(6):585-594. (PMID: 27897101)
Cancers (Basel). 2020 Sep 15;12(9):. (PMID: 32942567)
Front Oncol. 2018 Mar 21;8:78. (PMID: 29619344)
Cancer Manag Res. 2019 Apr 15;11:3227-3236. (PMID: 31114362)
Clin Genitourin Cancer. 2017 Apr;15(2):263-272.e4. (PMID: 27665259)
Front Oncol. 2019 Nov 15;9:1146. (PMID: 31799175)
Strahlenther Onkol. 2003 Jan;179(1):8-15. (PMID: 12540979)
Nat Commun. 2020 Oct 27;11(1):5424. (PMID: 33110073)
J Neurooncol. 2018 Jan;136(1):173-180. (PMID: 29076002)
Med Sci Monit. 2017 Jul 01;23:3217-3223. (PMID: 28667816)
Ann Surg Treat Res. 2016 Jun;90(6):322-7. (PMID: 27274508)
Gastroenterol Rep (Oxf). 2019 Aug 09;8(2):151-157. (PMID: 32280475)
Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895)
Front Oncol. 2020 Apr 17;10:432. (PMID: 32426265)
World Neurosurg. 2019 Jun;126:e1081-e1091. (PMID: 30880204)
Front Immunol. 2017 Oct 26;8:1349. (PMID: 29123517)
J Neurosurg. 2018 Sep;129(3):583-592. (PMID: 29099300)
Neurol Res. 2018 Nov;40(11):917-922. (PMID: 30074469)
Clin Neurol Neurosurg. 2016 Dec;151:86-91. (PMID: 27816892)
BMC Cancer. 2015 Sep 04;15:617. (PMID: 26341881)
Clin Cancer Res. 2011 Nov 15;17(22):6992-7002. (PMID: 21948231)
J Neurosci Rural Pract. 2021 Jan;12(1):88-94. (PMID: 33551616)
Oncoimmunology. 2015 Aug 24;5(2):e1075693. (PMID: 27057448)
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3287-3291. (PMID: 29286221)
J Neurooncol. 2013 Dec;115(3):521-2. (PMID: 24037498)
Strahlenther Onkol. 2003 Sep;179(9):620-5. (PMID: 14628128)
Biomedicines. 2020 Aug 20;8(9):. (PMID: 32825279)
J Transl Med. 2019 Apr 23;17(1):133. (PMID: 31014363)
Br J Cancer. 2012 Aug 7;107(4):695-9. (PMID: 22828611)
Mol Clin Oncol. 2018 Oct;9(4):453-458. (PMID: 30233797)
Clin Neurol Neurosurg. 2019 Jun;181:24-27. (PMID: 30974296)
Front Neurol. 2020 Oct 07;11:580101. (PMID: 33117267)
J Neurooncol. 2013 Aug;114(1):149-54. (PMID: 23780645)
J Neurooncol. 2017 May;132(3):463-471. (PMID: 28332000)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
Cells. 2017 Nov 22;6(4):. (PMID: 29165393)
Clin Cancer Res. 2014 Jan 1;20(1):187-98. (PMID: 24240114)
Gynecol Oncol. 2004 Jan;92(1):211-4. (PMID: 14751160)
Ann Transl Med. 2021 Apr;9(7):571. (PMID: 33987269)
World J Surg Oncol. 2019 Aug 31;17(1):152. (PMID: 31472673)
Front Oncol. 2021 Jun 08;11:695316. (PMID: 34178693)
J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676)
Crit Rev Oncol Hematol. 2021 Jul;163:103372. (PMID: 34062242)
J Clin Neurosci. 2019 Oct;68:1-8. (PMID: 31416731)
J Neurooncol. 2011 Oct;105(1):45-56. (PMID: 21384216)
Oncotarget. 2018 May 25;9(40):25860-25876. (PMID: 29899827)
J Immunol. 2012 Sep 15;189(6):2689-95. (PMID: 22956760)
World Neurosurg. 2021 May;149:e758-e765. (PMID: 33540096)
Acta Neuropathol. 1999 Oct;98(4):349-54. (PMID: 10502039)
Cells. 2020 Jan 25;9(2):. (PMID: 31991805)
Oncol Rev. 2020 Feb 18;14(1):461. (PMID: 32153727)
Ann Pathol. 2021 Apr;41(2):137-153. (PMID: 33712303)
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76. (PMID: 11181773)
Oncotarget. 2017 Jul 25;8(30):50117-50123. (PMID: 28223536)
BMC Cancer. 2020 Jan 15;20(1):35. (PMID: 31941467)
فهرسة مساهمة: Keywords: glioblastoma; hematological markers; prognosis; survival
تواريخ الأحداث: Date Created: 20211127 Latest Revision: 20211130
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8616081
DOI: 10.3390/cancers13225778
PMID: 34830935
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13225778